Skip to content
Transgene Logo
  • Home
  • Profile
    • About Transgene
    • Management Team
    • Board of Directors
    • Collaborations
    • Partners
    • Careers
  • Technology
    • Viral-based Immunotherapies
      • Therapeutic Vaccines
      • Oncolytic Viruses
    • myvac Platform
    • Invir.IO Platform
    • Publications and Presentations
  • Portfolio
    • Pipeline
    • TG4001
    • TG4050
    • TG6002
    • BT-001
    • Clinical trials FAQ
  • Investors
    • Financial Information
      • Key Figures
      • Financial Reports
      • Regulated Information
    • Stock Information
      • General
      • Stock Price
      • Shareholder Structure
      • Analysts
    • Investor Events & Presentations
      • Corporate Presentation
      • Webcasts
      • Financial Calendar
      • Investor Events
    • Corporate Governance
    • Annual General Meeting
  • News
    • Press Releases
    • Videos
  • Contacts
  • French

More about our products

Home/news HP/More about our products
  • View Larger Image

More about our products

More about our products

Transgene designs immunotherapeutics that exploit the natural mechanisms of the immune response to enable the patient to fight against the disease.

Discover our products

alcyon2019-06-25T09:25:01+02:00

Search

Recent Posts

  • Transgene and BioInvent receive approval from ANSM to proceed with Phase I/IIa trial of anti-CTLA4-armed oncolytic virus BT-001 in solid tumors
  • Transgene Appoints Gaëlle Stadtler as Director of Human Resources
  • Oddo BHF Digital Forum: January 7 to 13, 2021 – Virtual event
  • 10th Annual LifeSci Advisors Corporate Access Event: January 6 to 14, 2021 – Virtual event
  • Transgene and BioInvent receive CTA approval for Phase 1/2a trial of oncolytic virus BT-001 in solid tumors

Archives

  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • November 2013
  • October 2013
  • September 2013
  • May 2013
  • March 2013

Categories

  • BT-001
  • BT-001
  • Corporate presentation
  • Investor Event
  • Invir.IO
  • Myvac
  • News
  • news HP
  • Pexa-Vec
  • Press release
  • Publication
  • TB Program
  • TG1050
  • TG1050
  • TG3003
  • TG4001
  • TG4001
  • TG4010
  • TG4040
  • TG4050
  • TG6002
  • TG6002
  • Uncategorized
  • Webcast
  • Webcast

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

Search

Recent Posts

  • Transgene and BioInvent receive approval from ANSM to proceed with Phase I/IIa trial of anti-CTLA4-armed oncolytic virus BT-001 in solid tumors
  • Transgene Appoints Gaëlle Stadtler as Director of Human Resources
  • Oddo BHF Digital Forum: January 7 to 13, 2021 – Virtual event
  • 10th Annual LifeSci Advisors Corporate Access Event: January 6 to 14, 2021 – Virtual event
  • Transgene and BioInvent receive CTA approval for Phase 1/2a trial of oncolytic virus BT-001 in solid tumors

Archives

  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • November 2013
  • October 2013
  • September 2013
  • May 2013
  • March 2013

Categories

  • BT-001
  • BT-001
  • Corporate presentation
  • Investor Event
  • Invir.IO
  • Myvac
  • News
  • news HP
  • Pexa-Vec
  • Press release
  • Publication
  • TB Program
  • TG1050
  • TG1050
  • TG3003
  • TG4001
  • TG4001
  • TG4010
  • TG4040
  • TG4050
  • TG6002
  • TG6002
  • Uncategorized
  • Webcast
  • Webcast

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
Transgene sa
400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166 67405 Illkirch Graffenstaden Cedex - France | Phone: + 33 (0) 3 88 27 91 00 - Fax: + 33 (0) 3 88 27 91 11
© 2018 Transgene - All rights reserved
Legal Notice - Credits
Nous utilisons des cookies pour vous garantir la meilleure expérience sur notre site web. Si vous continuez à utiliser ce site, nous supposerons que vous en êtes satisfait.OkNon
Go to Top